Serum selenium concentrations in patients with intestinal metaplasia and in controls. The ECP-EURONUT-IM Study Group.
Serum selenium concentrations were measured in 126 matched sets of cases--patients with endoscopically proven intestinal metaplasia (IM) and two different controls, matched for age (+/- 3 years) and sex. The controls were either endoscopic controls (EC) who had endoscopically proven normal stomachs or non-endoscopic controls (NC), recruited from fracture and general surgical clinics. The cases and controls were recruited from four centres in the UK. Using a paired analysis, no significant difference was seen for IM vs EC either overall or between centres. However, these findings are compatible with reports of lower serum selenium in areas with a high risk of gastric cancer provided that selenium plays its role in the later stages of the disease.